BioPharmSignal logoBioPharmSignal

Biotech News

Milestone Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 13, 2026

Milestone Pharmaceuticals Inc. (MIST)Milestone Pharmaceuticals Inc.Earnings

MONTREAL and CHARLOTTE, May 06, 2026 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will report financial results for the first quarter

Related news

MISTMilestone Pharmaceuticals Inc.2026-08-04 20:01 EST

Milestone Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 12, 2026

MISTMilestone Pharmaceuticals Inc.2026-03-12 12:00 EST

Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026

LXRXLexicon Pharmaceuticals2026-04-30 12:00 EST

Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

RYTMRhythm Pharmaceuticals2026-04-09 12:00 EST

Rhythm Pharmaceuticals to Report First Quarter 2026 Financial Results on Tuesday, May 5, 2026

LXRXLexicon Pharmaceuticals2026-05-07 11:30 EST

Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates

RYTMRhythm Pharmaceuticals2026-05-05 11:00 EST

Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update

MLYSMineralys Therapeutics2026-04-29 20:05 EST

Mineralys Therapeutics to Announce First Quarter 2026 Financial Results and Host Conference Call on Wednesday, May 6, 2026

ALGSAligos Therapeutics2026-04-30 20:05 EST

Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026

MLYSMineralys Therapeutics2026-08-04 12:00 EST

Mineralys Therapeutics to Announce Second Quarter 2026 Financial Results and Host Conference Call on Tuesday, August 11, 2026

ALGSAligos Therapeutics2026-07-30 12:00 EST

Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026

View all latest news

Milestone Pharmaceuticals Inc.

Self-Administered Cardiac Rescue Therapy Milestone Pharmaceuticals develops rapid-onset nasal therapies for episodic cardiovascular conditions. CARDAMYST CARDAMYST is an FDA-approved etripamil nasal spray that adults can self-administer to convert symptomatic paroxysmal supraventricular tachycardia to sinus rhythm. Atrial Fibrillation...

Recent company news

MISTMilestone Pharmaceuticals Inc.2026-08-04 20:01 EST

Milestone Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 12, 2026

MISTMilestone Pharmaceuticals Inc.2026-07-03 01:30 EST

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MISTMilestone Pharmaceuticals Inc.2026-05-14 12:30 EST

Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

MISTMilestone Pharmaceuticals Inc.2026-05-13 11:11 EST

Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update

MISTMilestone Pharmaceuticals Inc.2026-05-06 12:00 EST

Milestone Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 13, 2026

Stock data

Close
1.18 USD
Market cap
164.34M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States